CLL in the Era of Targeted Therapies

Kanti R. Rai, MD; Jacqueline C. Barrientos, MD; and Richard R. Furman, MD
Published: Tuesday, Dec 12, 2017
Jacqueline Claudia Barrientos, MD

Jacqueline Claudia Barrientos, MD
Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia (CLL) by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival. These developments have been achieved by a better understanding of the underlying biology and the disease process. The current standard of care is to observe a patient with newly diagnosed CLL until disease-related symptoms warrant the need for therapy. Treatment is chosen based on the patients’ comorbidities and prognostic factors at the time therapy is initiated. Hence, physicians must carefully weigh the potential adverse effects and toxicities that can be expected from the chosen regimen. More important, prognostic markers should be obtained prior to initiating any line of therapy (frontline and at relapse) because certain drugs will not work for particular patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication